Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia

European Journal of Haematology

Volumn 66, Issue 6, 2001, Pages 408-411

  Faurschou, Mikkel ^a   Hasselbalch, Hans C ^a   Nielsen, Ove J ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Neutropenia; Rituximab; Thrombocytopenia; Treatment

Indexed keywords

AUTOANTIBODY; RITUXIMAB;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BLEEDING; CASE REPORT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; LEUKOCYTE COUNT; MALE; NEUTROPENIA; PRIORITY JOURNAL; REMISSION; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; FEMALE; HUMANS; MALE; NEUTROPENIA; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; REMISSION INDUCTION;

EID: 0034912522     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2001.066006408.x     Document Type: Article

References (11)

1. Haematological manifestations of systemic lupus erythematosus
2. Humoral immune abnormalities in T-cell large granular lymphocytic leukemia
3. Autoantibodies against peripheral blood cells appear early in HIV infection and their prevalence increases with disease progression
4. Idiopathic neutropenia: Antineutrophil antibodies and clinical correlations
5. Idiopathic thrombocytopenia and neutrocytopenia in childhood
6. Variable response to intravenous γ-globulin therapy in a patient with autoimmune neutropenia, thrombocytopenia, and pemphigoid
7. R in the treatment of chronic idiopathic thrombocytopenic purpura (ITP)
8. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia
9. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease
10. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
11. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of the patients respond to a 4-dose treatment program